Vilma Pacheco Barcia, Head of the Medical Oncology Department at Hospital Universitario La Luz, Gastrointestinal Cancer Unit at One Oncology Madrid Program, Quirónsalud, shared on LinkedIn:
A particularly meaningful milestone for PANTHEIA-SEOM study group. Our abstract from the PANTHEIA-SEOM Translational Study has been accepted for poster presentation at ESMO26. This work presents the first translational preliminary data from PANTHEIA-SEOM, exploring the genetic determinants of cachexia-related phenotypes in metastatic pancreatic cancer and the first steps of the PANTHEIA-SEOM gene signature.
These results reflect the strength of our ongoing collaboration with IMDEA Nutrición Institute, combining clinical oncology and translational research to advance our understanding of systemic inflammation, malnutrition and cancer cachexia in metastatic pancreatic cancer.
Ana Ramírez de Molina, Ricardo Ramos Ruiz, Andrea Ochaita, Cristina Mª Fernández, Lara P Fernández Álvarez.
Grateful to all the investigators, translational researchers working within PANTHEIA IMDEA Nutrición, Bellvitge Biomedical Research Institute – IDIBELL, engineers ARTIS Development | FocusedON, Raúl Guerra Hernández collaborators, and, above all, the patients who made this research possible.
I’m truly honored to lead the PANTHEIA-SEOM study group alongside the scientific committee Paula Jimenez Fonseca and Andres J. Muñoz Martin. It is amazing to see collaborative efforts translating into new scientific insights. Looking forward to sharing our findings with the oncology community at ESMO26 in Madrid!
Congratulations to all co-authors: Paula Cerdà Serdà, María De Toro Carmena, Jorge Adeva, Axel Mariño Méndez, Alberto Carmona Bayonas, Enrique Grande.
PANTHEIA-SEOM Translational study is funded with a Sociedad Española de Oncología Médica (SEOM) Grant 2024.
Read other articles about Pancreatic Cancer on OncoDaily.